Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Switzerland. 1. Has an essential or priority drug list been published in your country? (If so provide the link) Yes, Switzerland publishes such a list in the annex to the ordinance on the Essential Human Medicines…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Switzerland. 1. What is the definition of an orphan drug in your country? According to Art. 4 para. 1 lit. adecies TPA, an orphan drug is a medical product for human use for which it has…
Pharma Legal Handbook Join industry executives in staying informed on the market access and HTA process in Switzerland. 1. What is the definition of a vaccine in your country? In Switzerland, most of the regulations related to vaccines are contained in the Federal Act on Controlling Communicable Human Diseases (EpidA; Epidemiengesetz, EpG, SR.…
Switzerland For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World Health Organisation (WHO), Swissmedic also saw a Good Manufacturing Practice (GMP) agreement between Switzerland and the US FDA come into…
Europe Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to carve out a slice of this huge growth market. Those who made a bet on obesity years in advance are…
Global 2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated EU pharma legislation in Europe. Those companies producing COVID-19 vaccines and therapeutics saw revenues return to normal levels while others…
Switzerland As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment Humira, the newly spun-off company has been gearing up for its independence by preparing additional biosimilar launches, signing big partnership…
Switzerland At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges with the findings published in the Swiss Biotech Report 2023. The organisation also celebrated recent industry successes with its Swiss…
Switzerland Taken from the recently published Swiss Biotech Report 2023, these figures cover major public and private financing transactions in Swiss biotech in the past year; major financing categories; capital investments in Swiss biotech companies; revenues, R&D expenses, profit/loss and liquidity; as well as well as the total number of biotech…
Switzerland An extract from PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on price controls and reference pricing systems in Switzerland. Buy The Pharma Legal Handbook: Market Access & HTA – Switzerland here for £359. 1.1 How does price control at…
Global The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive Director Charles Gore outlines the MPP’s goals, how it interacts with an industry – innovative pharma – known to jealously…
Switzerland The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over five million more likely to follow. Elsewhere, Swiss health insurance premiums are set to see their largest rise since 2010…
See our Cookie Privacy Policy Here